Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02316496
Other study ID # REGAIN C13-2
Secondary ID
Status Terminated
Phase Phase 2
First received December 8, 2014
Last updated July 29, 2017
Start date September 23, 2015
Est. completion date January 2017

Study information

Verified date January 2017
Source Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main objective of this study is to evaluate the objective response rate at two months (complete disappearance of the disease and partial disappearance of the disease) obtained after administration of combination therapy with cetuximab and irinotecan in the patients with metastatic colorectal cancer.

Secondaries objectives will be assessed progression-free survival, overall survival, toxicity, quality of life.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date January 2017
Est. primary completion date January 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Signed and dated informed consent

- Histologically confirmed metastatic adenocarcinoma of the colon or rectum

- All Wild Type KRAS (exon 2 [codons 12-13], exon 3 [codons - 61]; exon 4 [codon 146]), NRAS (exon 2 [ codons 12-13] and exon 3 [codon 61) and BRAF (V600E) tumor ( local assessment performed either on primary tumor or metastasis)

- First line chemotherapy regimen with a fluoropyrimidine and Irinotecan (FOLFIRI) + cetuximab with initial partial or complete response and progressive disease (PD) with PD = 6 weeks after the last administration of cetuximab

- Other line(s) of therapy(ies) including the following drugs: second line oxaliplatin based chemotherapy with fluoropyrimidines (5FU or capecitabine) + bevacizumab and eventually regorafenib (possible but not mandatory) and progression or limiting toxicity to the last therapy with a minimum of 4 months between last injection of cetuximab and inclusion in this study

- At least one measurable lesion = 10 mm as assessed by CT-scan or MRI (Magnetic Resonance Imaging) according to RECIST v1.1 (All sites must be evaluated = 28 days prior to the enrolment)

- Age =18 years

- World Health Organization (WHO) Performance status (PS) 0-2

- The patient has adequate organ function, defined as :

Absolute neutrophil count (ANC) = 1.5 x 109/L, hemoglobin = 9 g/dL, and platelets = 100 x 109/L.Total bilirubin = 1.5 times upper limit of normal value (ULN), serum alkaline phosphatase level < 5 times ULN, Serum creatinine level <150µM/l

- For female patients of childbearing potential, negative pregnancy test within 7 days before starting the study drug

- Men and women are required to use adequate birth control during the study (when applicable) and until 6 months after the end of study treatment

- Registration in a national health care system (CMU included)

Exclusion Criteria:

- Previous chemotherapy other than adjuvant therapy with different combinations than those scheduled in first and second line treatment

- Presence of any KRAS, BRAF or NRAS mutation by allelic discrimination on tumor DNA

- Significant cardiovascular disease including unstable angina or myocardial infarction within 12 months before initiation of study treatment or a history of ventricular arrhythmia (treated or not)

- History or evidence of central nervous system metastasis (systematic CT-scan or MRI not mandatory if no clinical symptoms)

- Known allergy or hypersensitivity to cetuximab

- Previous or concurrent malignancy except for basal or squamous cell skin cancer, in situ carcinoma of the cervix, low-risk prostate cancer according to d'Amico classification or other solid tumors treated curatively and without evidence of recurrence for at least 5 years prior to the study

- Active or uncontrolled clinically serious infection

- Known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)-related illness

- Other serious and uncontrolled non-malignant disease

- Pregnancy

- Breast feeding

- Treatment with any other investigational medicinal product within 28 days prior to study entry

- Known Gilbert's syndrome

- Concomitant administration of live, attenuated virus vaccine such as yellow fever vaccine

- Concomitant use with St John's Wort

- Chronic inflammatory bowel disease and/or Bowel obstruction

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
cetuximab
cetuximab 500mg/m²/ IV infusion, (q2w)
Irinotecan
Irinotecan 180mg/m², in 500ml NaCl 0.9% solution, 90 min IV infusion (q2w)

Locations

Country Name City State
France Hôpital Beaujon Clichy
France Centre hospitalier Alpes Leman Contamine sur Arve
France Centre Georges François Leclerc Dijon
France CHD Vendée La Roche/ Yon
France Hôpital Privé Jean Mermoz Lyon
France Hôpital Européeen Marseille
France Institut Paoli-Calmettes Marseille
France CHU Caremeau Nîmes
France CHU Cochin Paris
France Hôpital Pitié Salpêtrière Paris
France Hôpital Saint Antoine Paris
France Hôpital Saint Louis Paris
France Hôpital Tenon Paris
France Clinique Armoricaine de Radiologie Saint Brieuc
France Groupe hospitalier Public du Sud de l'Oise -site de Senlis Senlis
France Centre de radiothérapie - Clinique Sainte Anne Strasbourg
France Hôpital Foch Suresnes
France Hôpitaux du Léman Thonon les Bains
France CHU Tours - Hôpital Trousseau Tours
France Clinique Générale Valence

Sponsors (1)

Lead Sponsor Collaborator
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective response rate (ORR) At 2 months
Secondary Objective response rate (ORR) Best response observed during investigational treatment combination. From the start of treatment until treatment failure up to 27 months
Secondary Disease control rate (DCR) The proportion of patients with tumor response (Complete response or partial response) or tumor stabilization as best response during study treamtent up to 27 months
Secondary Progression-free survival (PFS) Time from the date of inclusion to the date of the first progressive disease (RECIST criteria) or death (any cause) up to 27 months
Secondary Duration of response (DOR) Only for patients with tumor response (complete reposne or partial response) , from first confirmed response to first observed progression (PD) or death due to PD during study treatment up to 27 months
Secondary Time to response (TTR) Time from the date of inclusion to the date of the first confirmed CR or PR during study treatment up to 27 months
Secondary Time to progression (TTP) Time from the date of inclusion to the date of the first obseved progression (PD), or death due to progression during the study treatment up to 27 months
Secondary Time to treatment failure (TTF) Time from the date of inclusion to the date the decision was made to end the study treatment for any reason up to 27 months
Secondary Duration of stable disease (DoSD) Only for patient with a stable disease (SD) as best response during the study treatment, from date of inclusion to the first observed progression (PD) or death due to progression up to 27 months
Secondary Overall survival (OS) From the date of inclusion to the date of patient death, due to any cause, or to the last date the patient was known to be alive up to 27 months
Secondary Adverse Events (CTCAE v.4.03) Up to 27 months
Secondary Quality of life Using EORTC Quality of Life Questionnaire - C30 (QLQ-C30) and the Dermatology Life Quality Index (DLQI ) questionnaires Up to 27 months
Secondary Respose rate RAS and BRAF status in circulating tumoral DNA up to 27 months
Secondary PFS RAS and BRAF status in circulating tumoral DNA up to 27 months
See also
  Status Clinical Trial Phase
Recruiting NCT03941080 - Gut Microbiome Dynamics in Metastasized or Irresectable Colorectal Cancer
Completed NCT03213314 - HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies N/A
Completed NCT03647839 - Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer Phase 2
Recruiting NCT05057052 - Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis Phase 2
Completed NCT03251612 - Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer Phase 2
Completed NCT02380443 - AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer Phase 2
Recruiting NCT02149784 - Effectiveness Study of Resection of Primary Tumor in Stage IV Colorectal Cancer Patients Phase 3
Recruiting NCT01959061 - Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases Phase 4
Terminated NCT01668680 - Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma Phase 2
Recruiting NCT05068531 - Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients
Not yet recruiting NCT04525807 - Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella Theory
Completed NCT04482608 - The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival
Recruiting NCT03193710 - The Effects of General Anesthetics on Lymphocytes in Patients Undergoing Colorectal Cancer Resection and Mechanism Involved N/A
Recruiting NCT04854213 - PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients With LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells) N/A
Suspended NCT04108481 - Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer Phase 1/Phase 2
Completed NCT03142516 - FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status Phase 2
Completed NCT03144804 - A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer Phase 2
Active, not recruiting NCT01910610 - Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer Phase 3
Recruiting NCT05759728 - A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer Phase 1/Phase 2
Recruiting NCT04874207 - Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenib Phase 4